Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Fineline Cube Jul 24, 2026
Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Fineline Cube Jul 24, 2026
Company Deals

Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024

Fineline Cube Sep 3, 2024

SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...

Company Drug

China’s Evopoint Biosciences and UK’s GSK Eye Breakthrough Therapy Designations for Cancer Therapies

Fineline Cube Sep 3, 2024

BEIJING/LONDON—The Center for Drug Evaluation (CDE) in China has indicated that Evopoint Biosciences’ EZH2 inhibitor...

Company Deals

Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials

Fineline Cube Sep 3, 2024

HONG KONG—Duality Biologics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is...

Company

MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1

Fineline Cube Sep 3, 2024

SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...

Company Drug

Shandong Buchang Pharmaceuticals’ rhEPO-Fc for CKD Anemia Accepted for Review by China’s CDE

Fineline Cube Sep 3, 2024

BEIJING—The Center for Drug Evaluation (CDE) in China has accepted the market filing for a...

Company Drug

Biocon Biologics Resolves Patent Dispute with J&J, Secures Market Entry for Biosimilar Stelara

Fineline Cube Sep 2, 2024

Biocon Biologics Ltd, the biosimilars division of Indian pharmaceutical company Biocon Ltd (BOM: 532523, NSE:...

Company Drug

Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan

Fineline Cube Sep 2, 2024

Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US...

Company Drug

HutchMed Halts China Filing for Gastric Cancer Drug Fruquintinib Following Regulatory Feedback

Fineline Cube Sep 2, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013), a China-based biopharmaceutical company, has announced the withdrawal...

Company Drug

Novo Nordisk to Resubmit Wegovy Heart Failure Application with Updated Clinical Data

Fineline Cube Sep 2, 2024

Denmark’s pharmaceutical giant, Novo Nordisk (NYSE: NVO), has reported significant findings on the efficacy of...

Company Drug

AccurEdit Therapeutics’ Gene-Editing Drug ART001 Clears FDA Hurdle for US Clinical Trials

Fineline Cube Sep 2, 2024

SUZHOU—AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading Chinese specialist in gene editing therapies, has announced...

Company Deals

Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar

Fineline Cube Sep 2, 2024

BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing...

Company Deals

Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region

Fineline Cube Sep 2, 2024

SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with...

Company Deals R&D

Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital

Fineline Cube Sep 2, 2024

BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into...

Company Drug

Bio-Thera Solutions’ BAT2406 Biosimilar Gets Green Light for Clinical Trials in China

Fineline Cube Sep 2, 2024

GUANGZHOU—Bio-Thera Solutions (SHA: 688177), a leading biopharmaceutical company based in Guangzhou, has received approval from...

Policy / Regulatory

NMPA Unveils 82nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 2, 2024

The National Medical Products Administration (NMPA) has announced the release of the 82nd batch of...

Policy / Regulatory

Hainan Province Unveils Ambitious Three-Year Plan for Digital Health Innovation and Economy Expansion

Fineline Cube Sep 2, 2024

HAIKOU—The People’s Government of Hainan Province has unveiled the “Hainan Province’s Three Year Action Plan...

Policy / Regulatory

China Expands Medical Insurance Coverage to Include Assisted Reproductive Technology in 19 Regions

Fineline Cube Sep 2, 2024

BEIJING—As of September 1, 2024, a total of 19 provinces, municipalities, and the Xinjiang Production...

Company

BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman

Fineline Cube Sep 2, 2024

NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment...

Company Policy / Regulatory

China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns

Fineline Cube Sep 2, 2024

BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import,...

Company

Roche Diagnostics to Double Down on China with RMB 3 Billion Suzhou Plant Expansion

Fineline Cube Sep 2, 2024

SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the...

Posts pagination

1 … 337 338 339 … 699

Recent updates

  • Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification
  • Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance
  • Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136
  • Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market
  • Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Company Drug

Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136

Company Drug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.